CRISPR/Cas9 technology was used to delete the alternate exon 6B and redirect splicing to exon 6A. This results in expression of only the fetal isoform. RT-PCR of heart tissue confirmed that homozygotes exclusively express Scn5a with exon 6A and heterozygotes have approximately 70% Scn5a with exon 6A.